Factors Influencing Relapse-Free Survival in Merkel Cell Carcinoma of the Lower Limb—A Review of 60 Cases

2010 ◽  
Vol 76 (2) ◽  
pp. 393-397 ◽  
Author(s):  
Michael Poulsen ◽  
Caroline Round ◽  
Jacqui Keller ◽  
Lee Tripcony ◽  
Michael Veness
Keyword(s):  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Lower Limb ◽  
Merkel Cell ◽  
Relapse Free Survival ◽  
Free Survival ◽  
Factors Influencing

Real-world Merkel cell carcinoma outcomes from a tertiary care center.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e14098-e14098
Author(s):  
Theresa N Canavan ◽  
Nicole Adell Doudican ◽  
Mary Stevenson ◽  
Anna C. Pavlick ◽  
John Carucci
Keyword(s):  
Cell Carcinoma ◽  
Disease Progression ◽  
Merkel Cell Carcinoma ◽  
Checkpoint Inhibitors ◽  
Tertiary Care ◽  
Merkel Cell ◽  
New York University ◽  
Relapse Free Survival ◽  
Free Survival

e14098 Background: Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine carcinoma of the skin that is highly immunogenic. Checkpoint inhibitors (CPI) have recently revolutionized the treatment of advanced MCC. In this study we sought to better understand how CPI are used in an outpatient setting and to better define MCC outcomes associated with their use. Methods: We conducted a retrospective chart review of MCC patients seen in the New York University Hematology and Oncology Department from 2012-2018. Patient characteristics and treatment regimens were compared between those with and without disease progression at any point during follow-up. Results: Fifteen patients were identified, 46.7% of whom presented with nodal or distant disease (Table). Nine patients experienced relapse during follow-up. There were no MCC-specific deaths, and 92.3% of patients were without evidence of MCC at the end of follow-up. Ten patients were treated with one or more CPI (pembrolizumab, nivolumab, ipilimumab) either in the setting of first line systemic therapy (71.4%) or after experiencing disease progression (28.6%). There was a trend toward improved relapse free survival with CPI use (P = 0.054). Conclusions: Although recurrences were common, overall outcomes at the end of follow-up were very good. CPI were well tolerated and were associated with a trend toward improved relapse free survival. Patients with advanced stage MCC would benefit from consideration of CPI as part of their treatment options. [Table: see text]

Radiation Therapy Improves Overall Survival, Local Control and Metastasis-free Survival for Merkel Cell Carcinoma

2011 ◽  
Vol 81 (2) ◽  
pp. S683-S684
Author(s):  
O. Marina ◽  
C. Shah ◽  
L. Masterson ◽  
J.V. Antonucci ◽  
R.D. Keidan ◽  
...  
Keyword(s):  
Overall Survival ◽  
Radiation Therapy ◽  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Local Control ◽  
Merkel Cell ◽  
Free Survival

Multidisciplinary team approach for Merkel cell carcinoma: the European Institute of Oncology experience with focus on radiotherapy

2020 ◽  
pp. 030089162094420
Author(s):  
Dario Zerini ◽  
Filippo Patti ◽  
Francesca Spada ◽  
Nicola Fazio ◽  
Eleonora Pisa ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Multidisciplinary Approach ◽  
Unknown Primary ◽  
Team Approach ◽  
Merkel Cell ◽  
Limited Data ◽  
Free Survival ◽  
European Institute ◽  
Clinical Records

Objective: To review the therapeutic strategy in Merkel cell carcinoma (MCC) treated with radiotherapy (RT) discussed in a multidisciplinary tumour board. Methods: Clinical records of patients with a diagnosis of MCC and with an indication to undergo RT at the European Institute of Oncology between 2003 and 2018 were reviewed retrospectively. Results: Twenty-six patients were included in the analysis (median age 65 years, range 42–87). Nineteen received adjuvant RT, 4 exclusive RT, and the remainder palliative RT. Intensity-modulated RT was used in 13 cases, a 3D conformal technique in 11 cases, and stereotactic RT in 2 cases. No major toxicities were recorded. The median relapse-free survival (RFS) after adjuvant RT was 20.5 months, while for unknown primary MCC, it was 23 months. In the adjuvant setting, median polyomavirus-positive RFS was 21.5 months (range 1–49) and median polyomavirus-negative RFS was only 14 months (range 4–45). Overall, RFS of polyomavirus-positive and polyomavirus-negative patients was 10.5 and 8 months, respectively. After adjuvant RT, only 1 out of 10 patients had a recurrence in the RT field. At the time of data collection, 16 patients were alive with no evidence of disease, 1 patient was alive with advanced status of disease, 8 patients died of disease progression, and 1 patient died of other causes. Conclusions: The management of unknown primary and polyomavirus-positive cases, which had a better prognosis in our series, may benefit from a multidisciplinary approach, given the limited data available regarding optimal treatment.

Who Receives Standard of Care: Factors Influencing the Use of Sentinel Lymph Node Biopsy for Merkel Cell Carcinoma

2020 ◽  
Vol 231 (4) ◽  
pp. S286
Author(s):  
Michael J. Minarich ◽  
Elizabeth A. Handorf ◽  
Leah G. Stockton ◽  
Maitham A. Moslim ◽  
Stephanie H. Greco ◽  
...  
Keyword(s):  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Sentinel Lymph Node Biopsy ◽  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Standard Of Care ◽  
Lymph Node Biopsy ◽  
Merkel Cell ◽  
Factors Influencing ◽  
Node Biopsy

Adjuvant Radiation Therapy Correlates with Increased Disease-Free Survival in Stage I Merkel Cell Carcinoma

2011 ◽  
Vol 128 ◽  
pp. 44
Author(s):  
Stephen Poteet ◽  
Kevin Sexton ◽  
Alexander Schmidt ◽  
Ash Patel ◽  
Michael Osgood ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Disease Free Survival ◽  
Stage I ◽  
Adjuvant Radiation ◽  
Merkel Cell ◽  
Free Survival ◽  
Adjuvant Radiation Therapy ◽  
Disease Free

Adjuvant Radiation Therapy Increases Disease-Free Survival in Stage IB Merkel Cell Carcinoma

2014 ◽  
Vol 73 (5) ◽  
pp. 531-534 ◽  
Author(s):  
Kevin W. Sexton ◽  
Stephen P. Poteet ◽  
John Bradford Hill ◽  
Alexandra Schmidt ◽  
Ashit Patel ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Disease Free Survival ◽  
Adjuvant Radiation ◽  
Merkel Cell ◽  
Free Survival ◽  
Adjuvant Radiation Therapy ◽  
Stage Ib ◽  
Disease Free

scholarly journals Health-related quality of life trajectory of treatment-naive patients with Merkel cell carcinoma receiving avelumab

2020 ◽  
Vol 16 (27) ◽  
pp. 2089-2099
Author(s):  
Murtuza Bharmal ◽  
Sandra Nolte ◽  
Céleste Lebbé ◽  
Laurent Mortier ◽  
Andrew S Brohl ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Survival Rates ◽  
Progression Free Survival ◽  
Merkel Cell ◽  
Free Survival ◽  
Hrqol Data ◽  
Related Quality ◽  
Health Related ◽  
Treatment Naïve

Aim: To evaluate changes in health-related quality of life (HRQoL) in a Phase II trial (NCT02155647) of treatment-naive patients with metastatic Merkel cell carcinoma treated with avelumab (15-month follow-up). Materials & methods: Mixed-effect Models for Repeated Measures were applied to HRQoL data (FACT-M; EQ-5D-5L) to assess changes over time. Clinically derived progression-free survival was compared with HRQoL deterioration-free survival. Results: Overall, we saw relative stability in HRQoL among 116 included patients, with nonprogression associated with statistically and clinically meaningful better HRQoL compared with progressive disease. Deterioration-free survival rates (49–72% at 6 months, 40–58% at 12 months) were consistently higher/better compared with progression-free survival rates (41/31% at 6/12 months). Conclusion: These findings show unique longitudinal HRQoL data for treatment-naive metastatic Merkel cell carcinoma patients treated with avelumab. Clinical trial registration: NCT02155647 ( ClinicalTrials.gov ).

Effect of Patient Immune Status on the Efficacy of Radiation Therapy and Recurrence-Free Survival Among 805 Patients With Merkel Cell Carcinoma

2018 ◽  
Vol 102 (2) ◽  
pp. 330-339 ◽  
Author(s):  
Yolanda D. Tseng ◽  
Macklin H. Nguyen ◽  
Kelsey Baker ◽  
Maclean Cook ◽  
Mary Redman ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Immune Status ◽  
Recurrence Free Survival ◽  
Merkel Cell ◽  
Free Survival

148: Prognostic Factors Influencing Oncologic Outcomes in Merkel Cell Carcinoma: A Retrospective Population-Based Cohort Study

2021 ◽  
Vol 163 ◽  
pp. S63
Author(s):  
Megan McDonald ◽  
Arbind Dubey ◽  
Frances-Claire Eichorn ◽  
Alok Pathak
Keyword(s):  
Cohort Study ◽  
Prognostic Factors ◽  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Population Based ◽  
Oncologic Outcomes ◽  
Merkel Cell ◽  
Factors Influencing
Sign in / Sign up

Export Citation Format

Share Document